EXELA PHARMA Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EXELA PHARMA, and what generic alternatives to EXELA PHARMA drugs are available?
EXELA PHARMA has twenty-three approved drugs.
There are sixteen US patents protecting EXELA PHARMA drugs.
Summary for EXELA PHARMA
| US Patents: | 16 |
| Tradenames: | 20 |
| Ingredients: | 20 |
| NDAs: | 23 |
| Patent Litigation for EXELA PHARMA: | See patent lawsuits for EXELA PHARMA |
Drugs and US Patents for EXELA PHARMA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exela Pharma | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | SOLUTION;INTRAVENOUS | 018925-002 | Apr 5, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Exela Pharma | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 211086-001 | Sep 17, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Exela Pharma | ELCYS | cysteine hydrochloride | SOLUTION;INTRAVENOUS | 210660-001 | Apr 16, 2019 | RX | Yes | Yes | 11,679,125 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Exela Pharma | ELCYS | cysteine hydrochloride | SOLUTION;INTRAVENOUS | 210660-001 | Apr 16, 2019 | RX | Yes | Yes | 11,826,383 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Exela Pharma | VAZCULEP | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 204300-002 | Jun 27, 2014 | AP1 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| Exela Pharma | GLYRX-PF | glycopyrrolate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 210997-001 | Jul 11, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Exela Pharma | BLOXIVERZ | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 204078-001 | May 31, 2013 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
